We are live on ! Find out more
RVPHW

Reviva Pharmaceuticals Warrants
RVPHW

Delisted

RVPHW was delisted on the 12th of December, 2025.

Back to rankings

1 hedge funds and large institutions have $1K invested in Reviva Pharmaceuticals Warrants in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more capital invested

Capital invested by funds: $628 → $1K (+$372)

0.04% more ownership

Funds ownership: 0.01% → 0.05% (+0.04%)

50% less funds holding

Funds holding: 2 → 1 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
1
Holders Change
-1
Holders Change %
-50%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$2.33K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$612
2
CS
Clear Street
New York
-$16
Name Holding Trade Value Shares
Change 		Change in
Stake
VF
1
Virtu Financial
New York
$1K +$2.33K +16,100 New
UBS Group
2
UBS Group
Switzerland
– -$612 -3,734 Closed
CS
3
Clear Street
New York
– -$16 -100 Closed

RVPHW Hedge Fund Activity: Q1 2025 in Review

1 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Reviva Pharmaceuticals Warrants (RVPHW) for Q1 2025, worth a combined $1K — up 59% from $628 a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of RVPHW and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest buyer was Virtu Financial, opening a new position worth an estimated $2.33K. The largest seller was UBS Group, exiting entirely with an estimated $612 sold.

  • 1 institutional investor held Reviva Pharmaceuticals Warrants (RVPHW) as of Q1 2025, down from 2 in Q4 2024.
  • Funds reported $1K of Reviva Pharmaceuticals Warrants stock for Q1 2025, up 59% quarter-over-quarter.
  • 1 fund opened new Reviva Pharmaceuticals Warrants positions in Q1 2025 and 2 closed out, a net change of -1 holder.
  • The largest Reviva Pharmaceuticals Warrants buyer in Q1 2025 was Virtu Financial, an estimated $2.33K added.
  • The largest Reviva Pharmaceuticals Warrants seller in Q1 2025 was UBS Group, an estimated $612 sold.

Based on aggregated 13F filings for Q1 2025.